Table 4.
Characteristics of Stable and Unstable Exacerbator Patients by App Records or Recalled by Patient During Visit
| Stable Exacerbator | Unstable Exacerbator | p-value | |
|---|---|---|---|
| Exacerbations in app | |||
| n (%) | 19 (27.5) | 50 (72.5) | 0.092 |
| Age (years), mean (SD) | 64.22 (7.56) | 67.83 (7.95) | 0.725 |
| Sex (male), % | 78.9 | 84.0 | 0.143 |
| BMI (kg/m2), mean (SD) | 27.50 | 25.79 | 1.000 |
| Active smokers, (%) | 10.5 | 10.0 | 0.377 |
| Number of comorbidities ≥3, (%) | 42.1 | 54.0 | 0.062 |
| Dyspnea scale (mMRC) baseline≥2, (%) | 57.9 | 80 | 0.031 |
| Dyspnea scale (mMRC) at 6 months ≥2, (%) | 35.2 | 64.0 | 0.344 |
| CAT score baseline, m (SD) | 13.76 (9.05) | 15.85 (7.00) | 0.027 0.302 |
| CAT score at 6 months, m (SD) Drug treatment for COPD, (%) |
11.73 (4.96) | 15.12 (5.75) | |
| LAMA monotherapy | 0.0 | 8.0 | |
| LAMA-LABA combination | 31.6 | 36.0 | |
| LABA+ ICS combination | 10.5 | 4.0 | |
| Triple therapy | 57.9 | 52.0 | |
| Exacerbations recalled during visit | |||
| n (%) | 36 (52.2) | 33 (47.8) | 0.090 |
| Age (years), mean (SD) | 64.52 (7.19) | 69.36 (8.09) | 0.868 |
| Sex (male), % | 83.3 | 81.8 | 0.143 |
| BMI (kg/m2), mean (SD) | 27.50 (5.21) | 25.79 (3.86) | 0.108 |
| Active smokers, (%) | 16.7 | 3.0 | 0.116 |
| Number of comorbidities ≥3, (%) | 41.7 | 60.6 | 0.011 |
| Dyspnea scale (mMRC) baseline≥2, (%) | 61.5 | 87.9 | 0.046 |
| 45.5 | 69.7 | 0.010 | |
| Dyspnea scale (mMRC) at 6 months ≥2, (%) | 14.60 (9.18) | 16.03 (6.18) | 0.462 |
| CAT score baseline, m (SD) | 12.52 (5.44) | 16.00 (5.52) | 0.011 |
| CAT score in 6 months, m (SD) | |||
| Drug treatment for COPD, (%) | 5.6 | 6.1 | 0.826 |
| LAMA monotherapy | 33.3 | 36.4 | |
| LAMA-LABA combination | 8.3 | 3.0 | |
| LABA+ ICS combination | 52.8 | 54.5 | |
| Triple therapy |
Abbreviations: BMI, body mass index; mMRC, modified Medical Research Council; CAT, COPD Assessment Test; Triple therapy, LABA (long-acting beta-2 agonists) + LAMA (long-acting antimuscarinic agents) + ICS (inhaled corticosteroids).